Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | BECN1 | Q14457 | 7/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.50 |
| ▸ | FURIN | P09958 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168340 | 1.00 | RXFP1 (0.60) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168696 | 0.96 | RXFP1 (0.62) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10169252 | 0.95 | RXFP1 (0.59) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10169113 | 0.95 | RXFP1 (0.59) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168283 | 0.95 | RXFP1 (0.59) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168809 | 0.95 | RXFP1 (0.59) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168577 | 0.94 | RXFP1 (0.57) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168630 | 0.94 | RXFP1 (0.54) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168790 | 0.94 | RXFP1 (0.57) | RXFP1TFPIGRIN2DGRIN3BGRIN1 | |
| SCHEMBL10168791 | 0.94 | RXFP1 (0.57) | RXFP1TFPIGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | RXFP1 827/4885TFPI 2851/4885GRIN2D 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.